Sandoz, Inc. Initiates Two More Phase III Amgen (AMGN) Biosimilar Trials
1/19/2012 8:13:53 AM
Sandoz announced today that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen(R)) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta(R)). The filgrastim study is to evaluate the efficacy and safety of Sandoz's biosimilar filgrastim versus Neupogen(R) in breast cancer patients eligible for myelosuppressive chemotherapy treatment. It is expected to support extension of commercialization to the US, the largest global market for biologics. Sandoz's filgrastim biosimilar is already marketed under the brand name Zarzio(R) in more than 30 countries outside the United States.